vs

Side-by-side financial comparison of ONTO INNOVATION INC. (ONTO) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

ONTO INNOVATION INC. is the larger business by last-quarter revenue ($218.2M vs $207.3M, roughly 1.1× Ultragenyx Pharmaceutical Inc.). ONTO INNOVATION INC. runs the higher net margin — 12.9% vs -62.0%, a 75.0% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs -13.5%). ONTO INNOVATION INC. produced more free cash flow last quarter ($82.0M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 2.6%).

Onto Innovation Inc. is an American semiconductor company formed in 2019 from the merger of Rudolph Technologies, Inc. and Nanometrics Incorporated. It is a provider of process and process control equipment and software for microelectronic manufacturing industries.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

ONTO vs RARE — Head-to-Head

Bigger by revenue
ONTO
ONTO
1.1× larger
ONTO
$218.2M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+39.4% gap
RARE
25.9%
-13.5%
ONTO
Higher net margin
ONTO
ONTO
75.0% more per $
ONTO
12.9%
-62.0%
RARE
More free cash flow
ONTO
ONTO
$182.8M more FCF
ONTO
$82.0M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
2.6%
ONTO

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ONTO
ONTO
RARE
RARE
Revenue
$218.2M
$207.3M
Net Profit
$28.2M
$-128.6M
Gross Margin
50.7%
Operating Margin
10.9%
-54.7%
Net Margin
12.9%
-62.0%
Revenue YoY
-13.5%
25.9%
Net Profit YoY
-46.8%
3.5%
EPS (diluted)
$0.57
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ONTO
ONTO
RARE
RARE
Q4 25
$207.3M
Q3 25
$218.2M
$159.9M
Q2 25
$253.6M
$166.5M
Q1 25
$266.6M
$139.3M
Q4 24
$263.9M
$164.6M
Q3 24
$252.2M
$139.5M
Q2 24
$242.3M
$147.0M
Q1 24
$228.8M
$108.8M
Net Profit
ONTO
ONTO
RARE
RARE
Q4 25
$-128.6M
Q3 25
$28.2M
$-180.4M
Q2 25
$33.9M
$-115.0M
Q1 25
$64.1M
$-151.1M
Q4 24
$48.8M
$-133.2M
Q3 24
$53.1M
$-133.5M
Q2 24
$52.9M
$-131.6M
Q1 24
$46.9M
$-170.7M
Gross Margin
ONTO
ONTO
RARE
RARE
Q4 25
Q3 25
50.7%
Q2 25
48.2%
Q1 25
53.7%
Q4 24
50.2%
Q3 24
54.1%
Q2 24
52.9%
Q1 24
51.7%
Operating Margin
ONTO
ONTO
RARE
RARE
Q4 25
-54.7%
Q3 25
10.9%
-106.9%
Q2 25
12.7%
-64.8%
Q1 25
23.7%
-102.6%
Q4 24
16.1%
-74.3%
Q3 24
21.0%
-94.6%
Q2 24
20.2%
-79.1%
Q1 24
18.7%
-151.9%
Net Margin
ONTO
ONTO
RARE
RARE
Q4 25
-62.0%
Q3 25
12.9%
-112.8%
Q2 25
13.4%
-69.0%
Q1 25
24.0%
-108.5%
Q4 24
18.5%
-80.9%
Q3 24
21.0%
-95.7%
Q2 24
21.9%
-89.5%
Q1 24
20.5%
-156.8%
EPS (diluted)
ONTO
ONTO
RARE
RARE
Q4 25
$-1.28
Q3 25
$0.57
$-1.81
Q2 25
$0.69
$-1.17
Q1 25
$1.30
$-1.57
Q4 24
$0.98
$-1.34
Q3 24
$1.07
$-1.40
Q2 24
$1.07
$-1.52
Q1 24
$0.94
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ONTO
ONTO
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$603.1M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.0B
$-80.0M
Total Assets
$2.2B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ONTO
ONTO
RARE
RARE
Q4 25
$421.0M
Q3 25
$603.1M
$202.5M
Q2 25
$217.5M
$176.3M
Q1 25
$203.7M
$127.1M
Q4 24
$212.9M
$174.0M
Q3 24
$188.7M
$150.6M
Q2 24
$172.6M
$480.7M
Q1 24
$190.9M
$112.3M
Stockholders' Equity
ONTO
ONTO
RARE
RARE
Q4 25
$-80.0M
Q3 25
$2.0B
$9.2M
Q2 25
$2.0B
$151.3M
Q1 25
$1.9B
$144.2M
Q4 24
$1.9B
$255.0M
Q3 24
$1.9B
$346.8M
Q2 24
$1.8B
$432.4M
Q1 24
$1.8B
$140.3M
Total Assets
ONTO
ONTO
RARE
RARE
Q4 25
$1.5B
Q3 25
$2.2B
$1.2B
Q2 25
$2.1B
$1.3B
Q1 25
$2.1B
$1.3B
Q4 24
$2.1B
$1.5B
Q3 24
$2.1B
$1.5B
Q2 24
$2.0B
$1.6B
Q1 24
$2.0B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ONTO
ONTO
RARE
RARE
Operating Cash FlowLast quarter
$83.4M
$-99.8M
Free Cash FlowOCF − Capex
$82.0M
$-100.8M
FCF MarginFCF / Revenue
37.6%
-48.6%
Capex IntensityCapex / Revenue
0.6%
0.5%
Cash ConversionOCF / Net Profit
2.95×
TTM Free Cash FlowTrailing 4 quarters
$261.3M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ONTO
ONTO
RARE
RARE
Q4 25
$-99.8M
Q3 25
$83.4M
$-91.4M
Q2 25
$57.9M
$-108.3M
Q1 25
$92.0M
$-166.5M
Q4 24
$56.0M
$-79.3M
Q3 24
$67.2M
$-67.0M
Q2 24
$65.3M
$-77.0M
Q1 24
$57.1M
$-190.7M
Free Cash Flow
ONTO
ONTO
RARE
RARE
Q4 25
$-100.8M
Q3 25
$82.0M
$-92.7M
Q2 25
$44.2M
$-110.7M
Q1 25
$83.7M
$-167.8M
Q4 24
$51.4M
$-79.5M
Q3 24
$59.2M
$-68.6M
Q2 24
$53.0M
$-79.0M
Q1 24
$50.2M
$-193.9M
FCF Margin
ONTO
ONTO
RARE
RARE
Q4 25
-48.6%
Q3 25
37.6%
-58.0%
Q2 25
17.4%
-66.5%
Q1 25
31.4%
-120.5%
Q4 24
19.5%
-48.3%
Q3 24
23.5%
-49.2%
Q2 24
21.9%
-53.7%
Q1 24
21.9%
-178.2%
Capex Intensity
ONTO
ONTO
RARE
RARE
Q4 25
0.5%
Q3 25
0.6%
0.8%
Q2 25
5.4%
1.5%
Q1 25
3.1%
1.0%
Q4 24
1.8%
0.1%
Q3 24
3.2%
1.2%
Q2 24
5.1%
1.4%
Q1 24
3.0%
3.0%
Cash Conversion
ONTO
ONTO
RARE
RARE
Q4 25
Q3 25
2.95×
Q2 25
1.71×
Q1 25
1.44×
Q4 24
1.15×
Q3 24
1.27×
Q2 24
1.23×
Q1 24
1.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ONTO
ONTO

Systems And Software Revenue$173.8M80%
Parts Revenue$23.9M11%
Service Revenue$20.5M9%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons